| Literature DB >> 24639667 |
Pirkko Korsoff1, Leonie H Bogl2, Päivi Korhonen3, Antti J Kangas4, Pasi Soininen5, Mika Ala-Korpela6, Richard J Rose7, Risto Kaaja3, Jaakko Kaprio8.
Abstract
BACKGROUND: Prenatal exposure to androgens has been linked to masculinization of several traits. We aimed to determine whether putative female intra-uterine exposure to androgens influences anthropometric, metabolic, and reproductive parameters using a twin design.Entities:
Keywords: anthropometrics; lipoprotein profile; opposite-sex twin pairs; prenatal androgen exposure; reproductive history; twin testosterone transfer hypothesis
Year: 2014 PMID: 24639667 PMCID: PMC3945783 DOI: 10.3389/fendo.2014.00028
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Obesity measures, disease status, and reproductive characteristics for females from same-sex (SS) and opposite-sex (OS) dizygotic twin pairs.
| Variable | SS females ( | OS females ( | |
|---|---|---|---|
| Height (m), mean and SD | 1.66 ± 6.1 | 1.66 ± 5.6 | 0.19 |
| BMI (kg/m2), mean and SD | 24.2 ± 4.9 | 23.9 ± 4.4 | 0.34 |
| Waist circumference (cm) mean and SD | 81.9 ± 12.3 | 81.4 ± 11.7 | 0.48 |
| Hypertension (%) | 1.78 | 1.81 | 0.97 |
| Type 1 diabetes (%) | 0.89 | 0.65 | 0.60 |
| Type 2 diabetes (%) | 0.75 | 1.17 | 0.42 |
| Current pregnancy (%) | 10.2 | 7.4 | 0.06 |
| Age at the first pregnancy, years | 29.6 | 29.2 | 0.53 |
| Prevalence of biological children (%) | 62.2 | 66.1 | 0.12 |
| Number of biological children (%) | |||
| 1 Child | 32.1 | 31.3 | |
| 2 Children | 44.5 | 46.4 | |
| 3 Children | 16.4 | 16.2 | |
| 4 Children | 4.5 | 3.8 | |
| 5 Children | 2.6 | 2.3 | 0.97 |
| Spontaneous abortions (%) | |||
| Once | 16.2 | 13.6 | |
| 2 Or more | 4.1 | 4.2 | 0.37 |
| Infertility of >1 year duration (%) | 15.8 | 15.5 | 0.93 |
.
Missing values for height (.
Wave 5 of FinnTwin16.
Serum lipid and lipoprotein profile for females from same-sex (SS) and opposite-sex (OS) twin pairs.
| SS females ( | OS females ( | ||
|---|---|---|---|
| Large VLDL (and chylomicrons) (nmol/l) | 4.18 ± 4.01 | 3.51 ± 3.12 | 0.14 |
| Medium VLDL (nmol/l) | 13.79 ± 8.63 | 12.28 ± 6.70 | 0.17 |
| Small VLDL (nmol/l) | 54.08 ± 17.59 | 50.07 ± 16.79 | 0.05 |
| Large LDL (nmol/l) | 241.35 ± 56.90 | 230.61 ± 58.50 | 0.07 |
| Medium LDL (nmol/l) | 119.18 ± 30.70 | 114.03 ± 31.03 | 0.12 |
| Small LDL (nmol/l) | 136.64 ± 33.97 | 130.33 ± 33.99 | 0.10 |
| Large HDL (μmol/l) | 2.05 ± 0.78 | 2.06 ± 0.68 | 0.92 |
| Medium HDL (μmol/l) | 2.46 ± 0.45 | 2.37 ± 0.46 | 0.07 |
| Small HDL (μmol/l) | 4.87 ± 0.54 | 4.76 ± 0.56 | 0.06 |
| VLDL diameter (nm) | 36.53 ± 1.48 | 36.39 ± 1.47 | 0.50 |
| LDL diameter (nm) | 23.60 ± 0.18 | 23.60 ± 0.16 | 0.86 |
| HDL diameter (nm) | 10.10 ± 0.25 | 10.12 ± 0.23 | 0.45 |
| ApoA-1 (g/l) | 1.89 ± 0.22 | 1.88 ± 0.22 | 0.63 |
| ApoB (g/l) | 0.84 ± 0.19 | 0.81 ± 0.17 | 0.31 |
| ApoB/ApoA-1 ratio | 0.45 ± 0.10 | 0.44 ± 0.09 | 0.57 |
| Total triglycerides (mmol/l) | 1.13 ± 0.51 | 1.01 ± 0.43 | 0.04 |
| Extremely large VLDL-TG (mmol/l) | 0.01 ± 0.01 | 0.01 ± 0.01 | 0.05 |
| Total VLDL-TG (mmol/l) | 0.70 ± 0.44 | 0.62 ± 0.35 | 0.13 |
| Total cholesterol (mmol/l) | 4.99 ± 0.90 | 4.86 ± 0.89 | 0.23 |
| IDL-C (mmol/l) | 0.70 ± 0.16 | 0.68 ± 0.16 | 0.38 |
| LDL-C (mmol/l) | 1.72 ± 0.48 | 1.66 ± 0.49 | 0.20 |
| HDL-C (mmol/l) | 2.01 ± 0.42 | 1.99 ± 0.37 | 0.67 |
| HDL2-C (mmol/l) | 1.49 ± 0.45 | 1.47 ± 0.39 | 0.84 |
| HDL3-C (mmol/l) | 0.53 ± 0.06 | 0.52 ± 0.05 | 0.63 |
| HDL-C/LDL-C ratio | 1.26 ± 0.47 | 1.30 ± 0.44 | 0.43 |
.
Statistical significance at .
Wave 4 clinical subsample data from FinnTwin12 and FinnTwin16.